Episode 325: What Changed in the 2024 ASCO/ONS Antineoplastic Administration Safety Standards
Release Date: 08/16/2024
Episode 369: Lung Cancer Survivorship Considerations for Nurses
The ONS Podcast
“Just remember that these patients, these are human beings who had lung cancer. It’s a scary disease. And we don’t want to just say, ‘Oh, well, that’s a horrible disease. They probably won’t do well.’ These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology...
info_outline
Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer
The ONS Podcast
“That’s what metastatic breast cancer looks like now—patients can live an extended period of time. And sometimes I think we forget to cheer for stable disease. I tell patients they can live with weeds in their garden; they just can’t let the weeds take over their garden. And today we don’t have a cure. We live in a rapidly changing time in oncology, and so there’s just so much hope right now that we can offer patients,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN,...
info_outline
Episode 367: Pharmacology 101: PARP Inhibitors
The ONS Podcast
Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in...
info_outline
Episode 366: ONS 50th Anniversary: Generations of Nurses Keep Oncology in the Family
The ONS Podcast
“[My mom] would always be very inspirational whenever I would see her studying so long. And when she finally got to be a nurse, I always admired her vocation and compassion with her patients. She would always go above and beyond for all of her patients. I also got inspired a lot by my brother, as well, just seeing how passionate he was for caring for his patients for the families as well, and helping them deal with the any grief or loss that they were experiencing, Carolina Rios, MSN, RN, CPhT, told Valerie Burger, RN, MA, MS, OCN®, CPN, member of the ONS 50th anniversary planning...
info_outline
Episode 365: Radiation-Associated Secondary Cancers
The ONS Podcast
“From a radiation standpoint, the biggest thing we’re looking at is the treatment site, the dosage, and the way the radiation has been delivered. There are different ways that we can focus radiation using methods such as intensity-modulated radiotherapy, volumetric modulated arc therapy, flattening radiation beams, and proton beam therapy to try to help minimize radiation exposure to healthy tissues to minimize patient risk for secondary cancers,” ONS member Andrea Matsumoto, DNP, AGACNP-BC, AOCNP®, radiation oncology nurse practitioner at Henry Ford Health in Detroit, MI, told Jaime...
info_outline
Episode 364: How to Prepare for a Nursing Examination
The ONS Podcast
“Everyone will probably say this, but it is so true. Do not cram the night before the exam. The most important thing the night before the exam is to get a good night’s sleep. You might be so nervous. You’re like, ‘I can get any new information that matters right before the exam,’ but you can’t. Any information that you know you will have gotten in the time that you spent studying already. Really, you have to trust yourself,” Talia Lapidus, BSN, RN, professional staff nurse in the neonatal intensive care unit at UPMC in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS,...
info_outline
Episode 363: Lung Cancer Treatment Considerations for Nurses
The ONS Podcast
“A lot of other disease sites, they have some targeted therapies, they have some immunotherapies [IO]. In lung cancer, we have it all. We have chemo. We have IO. We have targeted therapies. We have bispecific T-cell engagers. We have orals, IVs. I think it’s just so important now that, particularly for lung cancer, you have to be well versed on all of these,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology...
info_outline
Episode 362: Pharmacology 101: MET Inhibitors
The ONS Podcast
“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it’s a really good marker because it’s found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS,...
info_outline
Episode 361: ONS 50th Anniversary: The Value of ONS Membership in Advancing the Oncology Nursing Profession
The ONS Podcast
“We spent time today discussing all the ways that owners can have a positive impact on career growth, whether you’re a bedside nurse or just in teaching, research, hospital leadership. More than career growth, I see ONS as kind of a barrier to burnout and a catalyst for professional self-care. I think that no matter what aspect of oncology care you’re involved in, it is a difficult and complex specialty. And I think with that can come a lot of challenges and tough days, and ONS brings a sense of community to that and, specifically, a community that is pushing cancer care forward,”...
info_outline
Episode 360: An Overview of Brain Malignancies for Oncology Nurses
The ONS Podcast
“Everyone’s brain is extremely heterogenic, so it’s different. You can put five of us in a room; we can all have the same diagnosis of a [glioblastoma multiforme], but all of ours can be different. They’re highly aggressive biologically. It’s a small area in a hard shell. So trying to get through the blood–brain barrier is different. There’s a lot of areas of hypoxia in the brain. There’s a lot of pressure there. The microbiology is very different—it’s a cold environment versus a hot environment—and then the pathways are just different,” Lori Cappello, MSN, APN-C,...
info_outline“These evidence-based standards provide a great framework for best practice in cancer care and the 2016 publication is extensively referenced. However, patient care mistakes and medication errors still happen. So, it’s imperative that we review the current literature and look for new evidence that’s been published,” ONS member MiKaela Olsen, DNP, APRN-CNS, AOCNS®, FAAN, clinical program director of oncology at Johns Hopkins Hospital and Johns Hopkins Health System told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the new Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology from ASCO and ONS.
Music Credit: “Fireflies and Stardust” by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 16, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge related to increasing safety of antineoplastic medication administration.
Episode Notes
- Complete this evaluation for free NCPD.
- Oncology Nursing Podcast™ episodes:
- ONS Voice articles:
- ONS books:
- ONS courses:
- Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards
- Oncology Nursing Forum article: ASCO/ONS Antineoplastic Therapy Administration Safety Standards
- ONS Learning Library: Safe Handling of Hazardous Drugs
To discuss the information in this episode with other oncology nurses, visit the ONS Communities.
To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the ONS Podcast Library.
To provide feedback or otherwise reach ONS about the podcast, email [email protected].
Highlights From This Episode
“The target population for these standards are, first, our patients—adult and pediatric patients with cancer who are receiving antineoplastic therapy—but as well as those who care for patients with cancer. And we’re not distinguishing between the healthcare worker, the caregiver, all people who care for patients with cancer, including those practitioners or healthcare workers that are not in a traditional oncology setting.” TS 3:25
“The audience is, first of all, oncology clinicians. We spent a lot of time on this panel writing the definition, so it was very clear who people were as we use terminology in the standards. So, an oncology clinician, when we refer to that in the standards, that's a licensed nurse, like a nurse or pharmacist, a licensed clinician, or it could be a non-licensed clinician like a patient care assistant or tech. So, we refer to people as clinicians that are licensed or unlicensed.” TS 4:14
“We need to define all types of therapy for cancer, and chemo is one type of treatment modality. The explosion of new therapies that include cellular therapies such as CAR T and other exciting emerging treatment options are not our traditional chemotherapy. And so the term antineoplastic was agreed upon for all these therapies to treat cancer. That definition in the standards is, and I quote, ‘All antineoplastic agents used to treat cancer regardless of the route.’ And that’s important because the previous guidelines were not as inclusive about that.” TS 6:58
“Another high-level change was the new language about the location of administration to include new healthcare settings. We know that antineoplastic medications are given in a variety of settings, not just your typical inpatient or ambulatory oncology infusion center anymore. We’ve got health plans that are increasingly developing strategies to direct patients to more convenient and less costly sites of service, such as the physician’s office or home infusion, unregulated sites, and more care is being given in these settings. So, it’s really important that we adapt the standards to make sure those patients treated in the home or in a freestanding center are given the same opportunity for safety and quality.” TS 8:39
“The other thing in Domain 1 that I think is crucial for nurses to understand, because it’s a big change, and we made this change based on the literature, looking at patient safety events related to inaccurate weight and height measurements. Domain 1 has a standard 1.7 that says weight and height are measured and documented in the medical record in metric units only. And I see that a lot when I’m going around the country. People still have their scales and pounds and their height in inches, and we’ve got to change that. We shouldn’t be converting things. Both the measurement and the documentation are verified by two individuals, one of whom is a licensed clinician. Prior to preparation and administration of a newly prescribed antineoplastic treatment plan.” TS 13:32
“That third verification is an independent safety check and, in my opinion, should be done in a quiet place where you can go through and do the safety checks that are listed in the standards quietly and thoughtfully, without being in the presence of the patient or caregiver. Those are done in an attempt to do some preliminary safety checks to make sure that when I go in the room to do my safety checks—we often call those bedside safety checks—that if I have an error before that with a dose or something, I’ve caught that before I get to the patient’s side.” TS 20:52